Ong S.T., Vogelzang N.J. (1996) Chemotherapy in malignant pleural mesothelioma. A review. J. Clin. Oncol. 14:1007-1017.
Wagner J.C., Sleggs E.A., Marchand P. (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 17:260-271.
Driscoll T.A., Baker G.J., Daniels S. (1993) Clinical aspects of malignant mesothelioma in Australia. Aust. N.Z. J. Med. 23(Suppl 1):19-25.
Vogelzang N.J., Weissman L.B., Herndon J.E. II (1994) Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J. Clin. Oncol. 12:1436-1442.
Antman K., Pass H.I., Recht A. (1989) Benign and malignant mesothelioma., DeVita V.T., Hellman S., Rosenberg S.A. (Eds.), Cancer: principles and practice of oncology, Philadelphia: JB Lippincott; 1399-1414.
Sugarbaker D.J., Heher E.C., Lee T.H. (1991) Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 192:10-15.
Ryan C.W., Herndon J., Vogelzang N.J. (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113.
Sculier J.P., Berghmans T., Castaigne C. (1998) Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 19:141-151.
Meert A.P., Berghmans T., Branle F. (1999) Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res. 19:4379-4390.
Gehan E.A. (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 13:346-353.
Sculier J.P., Paesmans M., Bureau G. (1996) A randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance in small cell lung cancer. J. Clin. Oncol. 14:2337-2344.
Planting A.S.T., Schellens J.H.M., Goey S.H. (1994) Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann. Oncol. 5:373-374.
Markman M., Cleary S., Pfeifle C. (1986) Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 58:18-21.
Zidar B.L., Green S., Pierce H.I. (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest. New Drugs 6:223-226.
Mintzer D.M., Kelsen D., Frimmer D. (1985) Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 69:711-712.
Planting A.S.T., van der Burg M.E.L., Gocy S.H. (1995) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann. Oncol. 6:613-615.
Eisenhauer E.A., Evans W.K., Murray N. (1988) A phase II study of VP-l6 and cisplatin in patients with unresectable malignant mesothelioma. an NCI Canada Clinical Trials Group Study. Invest. New Drugs 6:327-329.
Tsavaris N., Mylonakis N., Karvounis N. (1994) Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 11:299-303.
Middleton G.W., Smith I.E., O'Brien M.E.R. (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann. Oncol. 9:269-273.
Kasseyet S., Astoul P., Boutin C. (1999) Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer 85:1740-1749.
Chahinian A.P., Antman K., Goutsou M. (1993) Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol. 11:1559-1565.
Metintas M., Ozdemir N., Uçgun I. (1999) Cisplatin, mitomycin, and interferon-α2a combination chemotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 116:391-398.
Tansan S., Emri S., Selçuk T. (1994) Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 51:348-351.
Hastürk S., Tastepe I., Unlü M. (1996) Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J. Chemother. 8:159-164.
Pass H.W., Temeck B.K., Kranda K. (1995) A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann. Surg. Oncol. 2.
Trandafir L., Ruffié P., Borel C. (1997) Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur. J. Cancer 33:1900-1902.
Purohit A., Moreau L., Dietemann A. (1998) Weekly systemic combination of cisplatin and interferon α2a in diffuse malignant pleural mesothelioma. Lung Cancer 22:119-125.
Soulié P., Ruffié P., Trandafir L. (1996) Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alpha-2a. J. Clin. Oncol. 14:878-885.
Samuels B.L., Herndon J.E. II, Harmon D.C. (1998) Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma. A phase II study by the Cancer and Leukemia Group B. Cancer 82:1578-1584.
Byrne M.J., Davidson J.A., Musk A.W. (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J. Clin. Oncol. 17:25-30.
Nakano T., Chahinian A.P., Shinjo M. (1999) Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. A pilot phase II clinical trial and pharmacokinetic profile. Cancer 85:2375-2384.
Upham J.W., Musk A.W., van Hazel G. (1993) Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust. N.Z. J. Med. 23:683-687.
Dirix L.Y., van Meerbeeck J., Schrijvers D. (1994) A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann. Oncol. 5:653-655.
Carmichael J., Cantwell B.M.J., Harris A.L. (1989) A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur. J. Cancer Clin. Oncol. 25:911-912.
Samson M.K., Wasser L.P., Borden E.C. (1987) Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J. Clin. Oncol. 5:86-91.
Sorensen P.G., Bach F., Bork E. (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. 69:1431-1432.
Baas P., van Meerbeeck J., Groen H. (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann. Oncol. 11:697-700.
Oh Y., Perez-Soler R., Fossella F.V. (2000) Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest. New Drugs 18:243-245.
Pennucci M.C., Ardizzoni A., Pronzato P. (1997) Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. A phase II FONICAP trial. Cancer 79:1897-1902.
Breau J.L., Boaziz C., Morère J.F. (1993) Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III pleural mesothelioma. Eur. Resp. Rev. 3:223-225.
Shin D.M., Fossella F.V., Umsawasdi T. (1995) Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76:2230-2236.
Henß H., Fiebig H.H., Schildge J. (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11:118-120.
Ardizzoni A., Rosso R., Salvati F. (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 67:2984-2987.
Mbidde E.K., Harland S.J., Calvert A.H. (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 18:284-285.
Cantwell B.M.J., Franks C.R., Harris A.L. (1986) A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 18:286-288.
Raghavan D., Gianoutsos P., Bishop J. (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J. Clin. Oncol. 8:151-154.
Vogelzang N.J., Goutsou M., Corson J.M. (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother. Pharmacol. 27:239-242.
O'Reilly E.M., Ilson D.H., Saltz L.B. (1999) A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest. 17:195-200.
Colbert N., Vannetzel J.M., Izrael V. (1985) A prospective study of detorubicin in malignant mesothelioma. Cancer 56:2170-2174.
Mattson K., Giaccone G., Kirkpatrick A. (1992) Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 10:824-828.
Magri M.D., Foladore S., Veronesi A. (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann. Oncol. 3:237-238.
Bretti S., Berruti A., Dogliotti L. (1998) Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 84:558-561.
Magri M.D., Veronesi A., Foladore S. (1991) Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. Tumori 77:49-51.
Steele J.P.C., O'Doherty C.A., Shamash J. (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. 12:497-499.
Kaukel E., Koschel G., Gatzemeyer U. (1990) A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66:651-654.
Eisenhauer E.A., Evans W.K., Raghavan D. (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical trials Group Study. Cancer Treat. Rep. 70:1029-1030.
van Breukelen F.J.M., Mattson K., Giaccone G. (1991) Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer 27:1627-1629.
Hudis C.A., Kelsen D.P. (1992) Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest. New Drugs 10:103-106.
Bajorin D., Kelsen D., Mintzer D.M. (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat. Rep. 71:857-858.
Pinto C., Marino A., Guaraldi M. (2001) Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma. A phase II study. Am. J. Clin. Oncol. 24:143-147.
Halme M., Knuuttila A., Vehmas T. (1999) High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br. J. Cancer 80:1781-1785.
Solheim O.P., Saeter G., Finnanger A.M. (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br. J. Cancer 65:956-960.
Kindler H.L., Belani C.P., Herndon J.E. II (1999) Edatrexate (10-Ethyl-Deaza-Aminopterin) (NSC#626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the Cancer and Leukemia Group B. Cancer 86:1985-1991.
Klarskov Andersen M., Krarup-Hansen A., Martensson G. (1999) Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 24:39-43.
Içli F., Karaoguz H., Hastürk S. (1996) Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 15:207-213.
Falkson G., Hunt M., Borden E.C. (1992) An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest. New Drugs 10:337-343.
Zidar B.L., Metch B., Balcerzak S.P. (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group Study. Cancer 70:2547-2551.
Vogelzang N.J., Herndon J.E. II, Cirrincione C. (1997) Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer 79:2237-2242.
Dhingra H.M., Murphy W.K., Winn R.J. (1991) Phase II trial of 5,6-Dihydro-5azacytidine in pleural malignant mesothelioma. Invest. New Drugs 9:69-72.
Falkson G., Vorobiof D.A., Lerner H.J. (1983) A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 11:94-97.
Eagan R.T., Frytak S., Richardson R.L. (1986) Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat. Rep. 70:429.
Cantwell B.M.J., Earnshaw M., Harris A.L. (1986) Phase II study of a novel antifolate N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat. Rep. 70:1335-1336.
Steele J.P.C., Shamash J., Evans M.T. (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 18:3912-3917.
Boutin C., Irisson M., Guérin J.C. (1987) Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat. Rep. 71:205-206.
Kelsen D., Gralla R., Cheng E. (1983) Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat. Rep. 67:821-822.
Martensson G., Sörenson S. (1989) A phase II study of vincristine in malignant mesothelioma-a negative report. Cancer Chemother. Pharmacol. 24:133-134.
Falkson G., Vorobiof D.A., Simson I.W. (1987) Phase II trial of acivicin in malignant mesothelioma. Cancer Treat. Rep. 71:545-546.
Harvey V.J., Slevin M.L., Ponder B.A.J. (1984) Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-Fluorouracil and adriamycin. Cancer 54:961-964.
Sahmoud T., Postmus P.E., van Pottelsberghe C. (1997) Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer 33:2211-2215.
Tammilehto L., Maasilta P., Mäntylä M. (1994) Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann. Oncol. 5:949-950.
Kindler H.L., Millard F., Herndon J.E. II (2001) Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31:311-317.
van Meerbeeck J., Baas P., Debruyne C. (1999) A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 85:2577-2582.
Maksymiuk A.W., Marschke R.F., Tazelaar H.D. (1997) Phase II trial of topotecan for the treatment of mesothelioma. Am. J. Clin. Oncol. 21:610-613.
Knuuttila A., Ollikainen T., Halme M. (2000) Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma- a feasibility study. Anti-Cancer Drugs 11:257-261.
Vogelzang N.J., Herndon J.E. II, Miller A. (1999) High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann. Oncol. 10:597-600.
van Meerbeeck J., Debruyne C., van Zandwijk N. (1996) Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br. J. Cancer 74:961-963.
Astoul P., Picat-Joossen D., Viallat J.R. (1998) Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 83:2099-2104.
Castagneto B., Zai S., Mutti L. (2001) Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Results of a phase II study on 31 consecutive patients. Lung Cancer 31:303-310.
Mulatero C.W., Penson R.T., Papamichael D. (2001) A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31:67-72.
Ardizzoni A., Pennucci M.C., Castagneto B. (1994) Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am. J. Clin. Oncol. 17:80-82.
Christmas T.I., Manning L.S., Garlepp M.J. (1993) Effect of interferon-α2a on malignant mesothelioma. J. Interf. Res. 13:9-12.
Boutin C., Viallat J.R., van Zandwijk N. (1991) Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033-2037.
Von Hoff D.D., Metch B., Lucas J.G. (1990) Phase II evaluation of recombinant interferon-β (IFN-βser) in patients with diffuse mesothelioma: a Southwest Oncology Group Study. J. Interf. Res. 10:531-534.
Luce S., Paesmans M., Berghmans T. (1998) Revue critique des études randomisées évaluant le rôle de la radiothérapic thoracique adjuvante à la chimiothérapie dans le traitement du cancer bronchique à petites cellules au stade limité. Rev. Mal. Resp. 15:633-641.
Marino P., Preatoni A., Cantoni A. (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non-small cell lung cancer. Cancer 76:593-601.
Bramwell V.H.C., Williams C.J. (1997) Do authors of review articles use systematic methods to identify, assess and synthesize information?. Ann. Oncol. 8:1185-1195.
